Miralust (Montelukast)

Montelukast, the active ingredient in Miralust, is a leukotriene receptor antagonist presented as an oral tablet for oral use. It treats asthma, allergic rhinitis and exercise‑induced bronchoconstriction in adults and children.

GNH USA supplies Miralust as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montalust acts on the leukotriene pathway to control chronic airway diseases. - Asthma: reduces bronchoconstriction and inflammation, improving symptom control. - Allergic rhinitis: alleviates nasal congestion, sneezing and itching. - Exercise‑induced bronchoconstriction: prevents airway narrowing triggered by physical activity.

Montelukast is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate pain often transient. - Abdominal pain: discomfort or cramping in the stomach area. - Cough: occasional dry or productive cough. - Nausea: feeling of queasiness, sometimes with vomiting. - Sore throat: irritation or pain in the throat. - Diarrhoea: loose stools, usually self‑limiting.

Serious or Rare Side Effects: - Angioedema: swelling of face, lips or tongue requiring urgent care. - Hepatic injury: elevated liver enzymes or jaundice. - Neuropsychiatric events: agitation, depression or suicidal thoughts. - Anaphylaxis: severe allergic reaction with rash, difficulty breathing. - Stevens‑Johnson syndrome: rare skin blistering disorder. - Blood dyscrasias: unexplained bruising or low blood counts.

Before prescribing Montelukast, consider patient‑specific factors and monitor for adverse events. - Pregnancy: discuss potential risks with a healthcare professional; data are limited. - Breastfeeding: evaluate benefits versus potential infant exposure. - Hepatic impairment: use with caution; monitor liver function if clinically indicated. - Concomitant psychiatric conditions: observe for mood changes or suicidal ideation. - Drug interactions: review all current medications for possible interactions. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Montelukast may interact with other medicines; assess the clinical relevance before co‑administration.

Major Interactions (Avoid): - Phenobarbital: may reduce montelukast plasma concentrations. - Rifampin: strong enzyme inducer that can lower therapeutic effect.

Moderate Interactions (Monitor Closely): - Antidepressants (SSRIs, SNRIs): possible increase in neuropsychiatric side‑effects. - Warfarin: monitor INR as occasional alterations reported. - CYP2C9 inhibitors (e.g., fluconazole): may modestly raise montelukast levels.